This paper is only available as a PDF. To read, Please Download here.
Background: Because the symptoms of premenstrual dysphoric disorder (PMDD) are limited to the luteal phase of the menstrual cycle, the potential benefit of luteal-phase dosing has been hypothesized.
Objective: This multicenter, randomized, double-blind, placebo-controlled, parallel-group trial evaluated the efficacy and tolerability of enteric-coated fluoxetine 90 mg given once or twice during the luteal phase for the treatment of PMDD.
Methods: Study drug was given 14 and 7 days before expected menses during the luteal phase of 3 menstrual cycles. After a screening period and single-blind placebo lead-in period, eligible women were randomized to 1 of 3 treatment groups: enteric-coated fluoxetine 90 mg on both days (LPWD×2); placebo 14 days before menses and enteric-coated fluoxetine 90 mg 7 days before menses (LPWD×1); or placebo on both days (PLC). The primary efficacy measure was change from baseline in mean luteal-phase scores on the Daily Record of Severity of Problems (DRSP). Secondary efficacy measures included scores on the Rating Scale for Premenstrual Tension Syndrome, Clinician-Rated (PMTS-C); the Clinical Global Impression (CGI)—Severity scale; and the Patient Global Impression (PGI)—Improvement scale. Quality of life was assessed using the Sheehan Disability Scale.
Results: Two hundred fifty-seven women were randomized to treatment. At the end of the study, the LPWD×2 group had statistically significant improvements in DRSP total, DRSP mood subtotal, DRSP social functioning subtotal, PMTS-C, CGI-Severity, PGI-Improvement, and Sheehan Disability Scale work and family life scores compared with LPWD×1 and PLC (each measure, P < 0.05). There was also a statistically significant improvement in the score on the social life section of the Sheehan Disability Scale with LPWD×2 compared with PLC (P = 0.037). Across all treatment groups, 5 patients discontinued due to nonserious adverse events. Rates of discontinuation for any reason did not differ between the 3 treatment groups.
Conclusion: The findings of this study support the efficacy and tolerability of enteric-coated fluoxetine 90 mg given twice during the luteal phase of the menstrual cycle for the treatment of PMDD.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Therapeutics
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The epidemiology and social impact of premenstrual symptoms.Clin Obstet Gynecol. 1987; 30: 367-376
- Late luteal phase dysphoric disorder in young women.Am J Psychiatry. 1990; 147: 1634-1636
- The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: Attributable risk and risk factors.J Clin Epidemiol. 1992; 45: 377-392
- Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington, DC1994 Fourth Edition.
- Is premenstrual dysphoric disorder a distinct clinical disorder?.J Women's Health. 1999; 8: 663-679
- Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial.JAMA. 1997; 278: 983-988
- Fluoxetine in the treatment of premenstrual dysphoria.N Engl J Med. 1995; 332: 1529-1534
- Fluoxetine in the treatment of premenstrual dysphoria.Neuropsychopharmacology. 1997; 16: 346-356
- Long-term fluoxetine treatment of late luteal phase dysphoric disorder.J Clin Psychiatry. 1994; 55: 332-335
- Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant.J Clin Psychopharmacol. 1999; 19: 3-8
- FDA approves fluoxetine to treat premenstrual dysphoric disorder.FDA Talk Paper T00-31. July 6, 2000; (Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS01024.html. Accessed November 6, 2001)
- Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria.Psychopharmacol Bull. 1997; 33: 771-774
- Intermittent fluoxetine dosing in premenstrual dysphoric disorder.World J Biol Psychiatry. 2001; 2 (Abstract): 204S
- A naturalistic study of paroxetine in premenstrual syndrome: Efficacy and side-effects during ten cycles of treatment.Eur Neuropsychopharmacol. 1997; 7: 201-206
- Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?.J Clin Psychopharmacol. 1998; 18: 390-398
- Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study.Arch Fam Med. 1999; 8: 328-332
- Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double-blind, placebo-controlled crossover trial.J Clin Psychiatry. 1998; 59: 76-80
- Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome.J Clin Psychiatry. 1997; 58: 399-402
- The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.J Clin Psychiatry. 2000; 61: 851-857
- Daily rating of severity of problems form. Dept of Research Assessment and Training, NY State Psychiatric Institute, New York1990
- The measurement of premenstrual mood symptoms.J Affective Disord. 1999; 53: 269-273
- Guy W ECDEU Assessment Manual for Psychopharmacology, Revised. National Institute of Mental Health, Rockville, MD1976: 76-338
- Premenstrual tension syndrome: The development of research diagnostic criteria and new rating scales.Acta Psychiatr Scand. 1980; 62: 177-190
- Assessing psychiatric impairment in primary care with the Sheehan Disability Scale.Int J Psychiatry Med. 1997; 27: 93-105
- Design and Analysis of Experiments. John Wiley & Sons, New York1991: 50-94
- The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder.Br J Obstet Gynaecol. 2001; 108: 462-468
Accepted: January 9, 2002
© 2002 Published by Elsevier Inc.